Company to Concentrate on U.S. Pancreatic Cancer Detection Business, Strategic Asset Sales and Future Strategic Transaction
BERKELEY, Calif. and MAINZ, Germany, Feb. 17, 2026 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic firm specializing in early cancer detection, announced a series of strategic transactions designed to strengthen its liquidity position, pivot its business to focus on its U.S. pancreatic cancer detection program, and provide flexibility as the Company continues operations while evaluating growth opportunities and broader strategic alternatives.
On February 13, 2026, Mainz Biomed N.V. (the “Company”) entered into a securities purchase agreement for a $6.0 million private placement with investor David Lazar. The financing will be completed in two $3.0 million tranches via the issuance of Convertible Non-Redeemable Preferred Stock. The first $3.0 million closing was finalized on February 13, 2026. The second $3.0 million closing is expected following receipt of required stockholder approvals and prior to April 15, 2026. Net proceeds from the private placement are anticipated to fund ongoing operations, address outstanding liabilities, and preserve the Company’s ability to operate as it pursues strategic initiatives. In conjunction with the financing, the Company named David Lazar Chairman of the Board of Directors.
“Completing this financing provides the Company with critical runway and stability,” said David Lazar, Chair of Mainz Biomed’s Board of Directors. “Our immediate focus is to continue advancing and evaluating opportunities to grow our U.S. pancreatic screening program and stabilize the business. At the same time, we will be disciplined and thoughtful as we explore additional strategic alternatives that can unlock long-term value for stockholders.”
As the Company transitions its focus to developing its U.S. pancreatic cancer screening business, it will continue to assess opportunities to sell its colorectal cancer screening assets while winding down its German subsidiary. The Company is currently in discussions with several parties interested in its colorectal cancer assets. This allows the Company to significantly reduce operating expenses and extend its runway.
For a complete description of the transaction details above, please review the Company’s Form 8-K filed with the SEC on February 17, 2026.
Please follow us to stay updated:
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently conducting its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction (PCR)-based multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit or follow us on , and .
For investor inquiries, please contact
Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terms such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” — as well as other similar expressions that predict or indicate future events or trends or are not statements of historical fact. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised when relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to vary significantly from those described in these forward-looking statements: (i) failure to meet projected development and related targets; (ii) changes to applicable laws or regulations; (iii) the impact of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties outlined herein, as well as those discussed from time to time in other reports and public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information about these and other factors that may impact the Company’s expectations and projections can be found in its initial SEC filings, including its Form 20-F annual report filed on March 31, 2025 and its Form 6-K mid-year report filed on September 26, 2025. The Company’s SEC filings are publicly available on the SEC’s website at www.sec.gov. Any forward-looking statement in this press release is based solely on information available to Mainz Biomed at the time and speaks only as of the date it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, made from time to time — whether due to new information, future developments or other reasons — except as required by law.
